Cao Wei-guo, Zhao Ren, Xi Wen-qi, Ma Tao, Li Hao, Xu Hao-ping, Che Jin-feng, Jin Ye-ning
Department of Chemoradiation Oncology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, China.
Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):225-7.
To investigate the effect of preoperative radiotherapy or chemoradiotherapy on the sphincter preservation and local tumor control as well as survival for the patient with locally advanced middle-low rectal cancer.
121 locally advanced middle-low rectal cancer patients were treated with preoperative radiotherapy or chemoradiotherapy followed by surgery after rest of 4 to 6 weeks. 103 of these patients who underwent radical surgery were finally included in this study. The irradiation regimen was: 40 Gy/4 - 5 weeks, whereas 57 of these 103 patients received concurrent chemotherapy of 5-Fu or Xeloda. Sphincter-preserving surgery was performed in 59 patients and abdominoperineal resection in 44 patients. The survival was estimated by Kaplan-Meier model, and the differences between groups were compared using Log rank test. Multivariate analysis was performed by Cox's model.
Ten patients (9.7%) achieved a complete pathological response (pCR) to preoperative radiotherapy or chemoradiotherapy. The sphincter preservation rate was 57.3%. The 3-year overall survival (OS) and disease free survival (DFS) was 66.3% and 59.5%, respectively. Univariate analysis showed that pCR and postoperative pTNM stage were prognostic factors affecting survival, whereas, only pTNM stage was an independent prognostic factor (P = 0.003) by multivariate analysis.
Neoadjuvant preoperative radiotherapy and chemoradiotherapy is effective in local tumor control and improving survival for locally advanced middle-low rectal cancer, which can raise the rate of sphincter-preserving surgery, and achieve comparable result to abdominoperineal resection.
探讨术前放疗或放化疗对局部进展期中低位直肠癌患者保肛及局部肿瘤控制和生存的影响。
121例局部进展期中低位直肠癌患者接受术前放疗或放化疗,休息4至6周后进行手术。最终纳入本研究的103例接受根治性手术的患者。照射方案为:40 Gy/4 - 5周,其中103例患者中有57例接受了5-氟尿嘧啶或希罗达同步化疗。59例行保肛手术,44例行腹会阴联合切除术。采用Kaplan-Meier模型估计生存率,用Log rank检验比较组间差异。通过Cox模型进行多因素分析。
10例患者(9.7%)对术前放疗或放化疗达到完全病理缓解(pCR)。保肛率为57.3%。3年总生存率(OS)和无病生存率(DFS)分别为66.3%和59.5%。单因素分析显示,pCR和术后pTNM分期是影响生存的预后因素,而多因素分析显示只有pTNM分期是独立预后因素(P = 0.003)。
新辅助术前放疗和放化疗对局部进展期中低位直肠癌的局部肿瘤控制和提高生存率有效,可提高保肛手术率,与腹会阴联合切除术效果相当。